Citation Impact
Citing Papers
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
2010 StandoutScience
Genetic Influences on Brain Gene Expression in Rats Selected for Tameness and Aggression
2014 StandoutNobel
Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors
2007
Ionotropic and metabotropic glutamate receptor structure and pharmacology
2005
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application
2006
Ketamine and Rapid-Acting Antidepressants: A Window into a New Neurobiology for Mood Disorder Therapeutics
2014
Glutamate receptor ion channels
2005 Standout
RIM1α and Interacting Proteins Involved in Presynaptic Plasticity Mediate Prepulse Inhibition and Additional Behaviors Linked to Schizophrenia
2010 StandoutNobel
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
2010 Standout
Ferroptosis: Death by Lipid Peroxidation
2015 Standout
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
2014 Standout
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
2008 Standout
Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection
2008
Network pharmacology: the next paradigm in drug discovery
2008 Standout
Trends in GPCR drug discovery: new agents, targets and indications
2017 Standout
Impulsivity, Compulsivity, and Top-Down Cognitive Control
2011 Standout
Psychedelics
2016 Standout
REVIEW ON CPP: Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade
2007 Standout
Allosteric Modulation of Family C G-Protein-Coupled Receptors: from Molecular Insights to Therapeutic Perspectives
2011
From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment
2011
Glutamate and Schizophrenia: Phencyclidine, N‐Methyl‐d‐Aspartate Receptors, and Dopamine–Glutamate Interactions
2007
Molecular Dynamics Simulation for All
2018 Standout
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update
2011 Standout
Benzimidazole: An emerging scaffold for analgesic and anti-inflammatory agents
2014
Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor
2010 StandoutNatureNobel
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
2011 StandoutNature
Regulation of Ferroptotic Cancer Cell Death by GPX4
2014 Standout
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
2011 Standout
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
2008
Cellular and Synaptic Mechanisms of Anti-NMDA Receptor Encephalitis
2010 Standout
The structure and function of G-protein-coupled receptors
2009 StandoutNatureNobel
Distinct Neuronal Coding Schemes in Memory Revealed by Selective Erasure of Fast Synchronous Synaptic Transmission
2012 StandoutNobel
Variations in extracellular levels of dopamine, noradrenaline, glutamate, and aspartate across the sleep–wake cycle in the medial prefrontal cortex and nucleus accumbens of freely moving rats
2005
How were new medicines discovered?
2011 Standout
Lysergic acid diethylamide and [−]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex
2004
9H-Xanthene-9-carboxylic acid [1,2,4]oxadiazol-3-yl- and (2H-tetrazol-5-yl)-amides as potent, orally available mGlu1 receptor enhancers
2005
The acute effects of NMDA antagonism: From the rodent to the human brain
2008
AKT/PKB Signaling: Navigating the Network
2017 Standout
Increased expression of the Vesicular Glutamate Transporter-1 (VGLUT1) in the prefrontal cortex correlates with differential vulnerability to chronic stress in various mouse strains: Effects of fluoxetine and MK-801
2011
Endogenous serotonin and serotonin2Creceptors are involved in the ability of M100907 to suppress cortical glutamate release induced by NMDA receptor blockade
2008
The molecular neurobiology of depression
2008 StandoutNature
NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease
2013 Standout
Development of allosteric modulators of GPCRs for treatment of CNS disorders
2013
Lipoxygenase and Leukotriene Pathways: Biochemistry, Biology, and Roles in Disease
2011
Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals
2014 Standout
Azole-Based Energetic Salts
2011 Standout
Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis
2016 Standout
Tuning Reactivity and Site Selectivity of Simple Arenes in C–H Activation: Ortho-Arylation of Anisoles via Arene–Metal π-Complexation
2014
Mild metal-catalyzed C–H activation: examples and concepts
2016 Standout
Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs
2013
Molecular Docking and Structure-Based Drug Design Strategies
2015 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Metabotropic glutamate receptors as a strategic target for the treatment of epilepsy
2006
Review: Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review
2007
Drugs in the tetrazole series. (Review)
2007
On the Mechanism of Cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the Role of Lipid Peroxidation in Ferroptotic Cell Death
2017 Standout
Reversible Photocontrol of Biological Systems by the Incorporation of Molecular Photoswitches
2013 StandoutNobel
About Sleep's Role in Memory
2013 Standout
NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex
2004
Update on the Development of Antagonists of Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2). From Lead Optimization to Clinical Proof-of-Concept in Asthma and Allergic Rhinitis
2012
Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
2007
Enhanced cocaine responsiveness and impaired motor coordination in metabotropic glutamate receptor subtype 2 knockout mice
2005
Works of Christopher Baccei being referenced
5-Lipoxygenase-Activating Protein (FLAP) Inhibitors. Part 4: Development of 3-[3- tert -Butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1 H -indol-2-yl]-2,2-dimethylpropionic Acid (AM803), a Potent, Oral, Once Daily FLAP Inhibitor
2011
Sodium [2′-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4′-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): A potent, selective prostaglandin D2 receptor antagonist
2010
Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis
2011
Comparison of the effects of diazepam, the CRF1 antagonist CP-154,526 and the group II mGlu receptor agonist LY379268 on stress-evoked extracellular norepinephrine levels
2005
Effects of ketamine and n-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268
2003
5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)—A potent FLAP inhibitor
2009
Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis
2009
Pharmacological Blockade of the DP2 Receptor Inhibits Cigarette Smoke-Induced Inflammation, Mucus Cell Metaplasia, and Epithelial Hyperplasia in the Mouse Lung
2009
Group II mGlu Receptor Activation Suppresses Norepinephrine Release in the Ventral Hippocampus and Locomotor Responses to Acute Ketamine Challenge
2003
Pharmacology of AM211, a Potent and Selective Prostaglandin D2 Receptor Type 2 Antagonist That Is Active in Animal Models of Allergic Inflammation
2011
5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)—A potent FLAP inhibitor suitable for topical administration
2010
Phenyl-tetrazolyl Acetophenones: Discovery of Positive Allosteric Potentiatiors for the Metabotropic Glutamate 2 Receptor
2004
5-Lipoxygenase-Activating Protein Inhibitors: Development of 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103)
2009